The biotech's biggest shareholder just made a move that rattled Karuna's other shareholders.
News & Analysis: Karuna Therapeutics Inc
Incredibly, they're almost all health stocks, including 7 biotechs, an eye surgery platform, and a medical device company.
Is the stock a buy now that the price has dropped?
These clinical-stage biotech stocks have delivered eye-popping gains in 2019, but what about the road ahead?
Karuna Therapeutics Tests Our Theories!
History is littered with promising phase 2 drugs that failed upon further testing. Investors shouldn't get caught up in the hype.
The pharma company announced the pricing of a public stock offering.
Positive clinical trial results recently sent this stock soaring, but can it climb further?
The great news from a clinical study of experimental schizophrenia drug KarXT still has investors excited about the biotech stock.
Some surprising events lifted these stocks.